Kv11.1, also known as hERG (human Ether-à-go-go Related Gene), is predominantly expressed in cardiac myocytes and the central nervous system, where it is essential for repolarizing the cardiac action potential and regulating neuronal excitability. Dysfunction or pharmacological inhibition of hERG channels leads to delayed cardiac repolarization, manifesting as drug-induced long QT syndrome—a potentially fatal arrhythmia of major concern in drug development. Because of this, regulatory agencies including the FDA mandate routine screening of new drug candidates for Kv11.1 inhibition.